Back to results
US 2020/0384112 A1Published application
Saposin c pharmaceutical compositions and methods of treating cancer
AssigneeBexion Pharmaceuticals Inc.
InventorsEllen K. Monson, Xiaochen Wei, Ray Takigiku, Charles A. Cruze, III, Joseph W. Wyse
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.
Claims21
1-41. (canceled)
A composition comprising:
- a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 with zero to four amino acid insertions, substitutions, or deletions;
- a phosphatidylserine lipid;
- a buffer at pH 5.0 to 8.0;
- trehalose;
- and
- water,
- wherein the polypeptide is at a concentration of 0.4 to 5.0 mg/ml,
- wherein the molar ratio of the phosphatidylserine lipid to the polypeptide is in the range of 8:1 to 20:1, and
- wherein the phosphatidylserine lipid and the polypeptide are associated together in the form of vesicles suspended in the water.
7 more elements
An in vitro method for assaying potency of a composition comprising saposin C and an anionic phospholipid, the method comprising:
- carrying out a first assay that comprises contacting the composition with glucocerebrosidase and 4-methylumbelliferyl-β-D-glucopyranoside (4-MUG);
- carrying out a control assay that comprises contacting a reference standard composition with glucocerebrosidase and 4-MUG;
- determining the level of 4-methylumbellierone (4-MU) formed as a result of cleavage of 4-MUG in the first assay;
- determining the level of 4-MU formed as a result of cleavage of 4-MUG in the control assay;
- and
- comparing the level of 4-MU formed in the first assay to the level of 4-MU in the control assay, thereby determining the relative potency of the composition.
3 more elements
Dependencies are inferred from the claim text.